在慢性全闭塞中进行冠状动脉穿孔的前胺 皮肤冠状动脉干预
Sant Kumar1,2, Sudhir Thotakura1,3, Kathleen E Kearney1
1Division of Cardiology, Department of Medicine, University of Washington, Seattle, WA, USA.
Journal of cardiovascular pharmacology
|January 22, 2026
概括
对于慢性全闭性皮肤通道冠状动脉干预 (CTO PCI) 穿孔而言,使用前胺是安全的. 这项研究发现,接受前胺和不接受前胺的患者之间的住院或1年结果没有显著差异.
科学领域:
- 心脏病学 心脏病学
- 干预心脏病学 干预心脏病学
- 血管医学 血管医学
背景情况:
- 在皮肤冠状动脉干预 (PCI) 中,用质氨酸逆转未分离的肝素是常见的.
- 关于原胺的安全性和慢性全闭性PCI (CTO PCI) 相关穿孔的结果的数据有限.
- 在这种特定的高风险场景中评估蛋白质胺的影响对于临床实践至关重要.
研究的目的:
- 评估CTO PCI期间冠状动脉穿孔的患者中与原胺剂的使用相关的安全性和临床结果.
- 为了比较在医院和1年内因任何原因死亡率,心脏栓塞和心肌梗塞的患者接受前胺和那些没有接受前胺.
主要方法:
- 从2019年1月到2023年12月,对1503个CTO PCI程序进行了回顾性分析.
- 冠状动脉穿孔的患者 (n=199) 根据蛋白质胺剂的使用进行了分层.
- 针对调整后的分析,使用了治疗权重的逆概率 (IPTW) 和双重可靠的逻辑回归.
主要成果:
- 在医院治疗的结果,包括死亡,心周病变和周围手术性心脏病发作,在蛋白质胺和非蛋白质胺组之间是可比的.
- 没有观察到急性支架血栓形成或蛋白胺反应.
- 经过调整后的分析显示,蛋白质胺使用与不良住院或一年内因任何原因死亡之间没有显著的关联.
结论:
- 对于CTO PCI相关的穿孔而言,原氨酸的使用似乎是安全的.
- 在这种情况下,没有证据表明使用前胺有额外的临床益处.
- 目前在CTO PCI穿孔中使用质氨酸的做法需要根据这些发现重新评估.
相关概念视频
01:21Coronary Circulation
6.8K
The heart, an organ critical to survival, gets nourishment not from the blood it pumps but from a separate circulation system known as coronary circulation. This is the shortest circulation in the body and is responsible for supplying the heart with the nutrients it needs to function effectively.
Coronary circulation begins at the base of the aorta, where two main arteries arise—the left and right coronary arteries. These arteries encircle the heart in the coronary sulcus and supply the...
Coronary circulation begins at the base of the aorta, where two main arteries arise—the left and right coronary arteries. These arteries encircle the heart in the coronary sulcus and supply the...
6.8K
01:30Coronary Artery Disease I: Introduction
912
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
912
01:26Coronary Artery Disease II: Pathophysiology
390
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
390
01:30Acute Coronary Syndrome I: Introduction
877
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
877
01:26Acute Coronary Syndrome V: Nursing Management
287
Nursing Assessment:Nursing management of acute coronary syndrome (ACS) involves taking the patient's history, focusing on primary complaints such as chest pain, dyspnea, and excessive sweating (diaphoresis), as well as other symptoms like back or jaw pain, nausea, vomiting, palpitations, dizziness, and fatigue. The nurse also reviews the patient's history of cardiac events, risk factors such as hypertension, diabetes, smoking, family history, and current medications.In the objective assessment,...
287
01:27Coronary Artery Disease V: Interprofessional Care
222
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
222